The formation of the myelin membrane of the oligodendrocyte in the CNS is a fundamental process requiring the coordinated synthesis of many different components. The myelin membrane is particularly rich in lipids, however, the regulation of this lipid synthesis is not understood. In other cell types, including Schwann cells, the myelin-forming cells of the PNS, lipid synthesis is tightly regulated by the sterol regulatory element-binding protein (SREBP) family of transcription factors, but this has not been previously shown in oligodendrocytes. We investigated SREBPs' role during oligodendrocyte differentiation in vitro. Both SREBP-1 and SREBP-2 were expressed in oligodendrocyte precursor cells and differentiating oligodendrocytes. Using the selective site-1 protease (S1P) inhibitor PF-429242, which inhibits the cleavage of SREBP precursor forms into mature forms, we found that preventing SREBP processing inhibited process growth and reduced the expression level of myelin basic protein, a major component of myelin. Further, process extension deficits could be rescued by the addition of exogenous cholesterol. Blocking SREBP processing reduced mRNA transcription and protein levels of SREBP target genes involved in both the fatty acid and the cholesterol synthetic pathways. Furthermore, de novo levels and total levels of cholesterol synthesis were greatly diminished when SREBP processing was inhibited. Together these results indicate that SREBPs are important regulators of oligodendrocyte maturation and that perturbation of their activity may affect myelin formation and integrity.
Oligodendrocytes are the myelin-forming cells of the CNS. They synthesize the myelin sheath which wraps around axons, insulates them and allows for efficient nerve conduction. Throughout development, oligodendrocyte precursor cells (OPCs) progress through distinct morphological and antigenic stages of differentiation before producing myelin (Pfeiffer et al. 1993; Miller 2002) . Immature oligodendrocytes express galactocerebroside (GalC) and initiate process extension to develop a complex network of processes. During myelination, oligodendrocytes elaborate tremendous amounts of cellular membrane highly enriched in lipids, in particular cholesterol and glycosphingolipids (Gielen et al. 2006) . The myelination process also involves the activation of numerous enzymes of lipid metabolism necessary for myelin lipid synthesis and the synthesis and transport of specific myelin proteins, including proteolipid protein (PLP) and myelin basic protein (MBP). One of the major regulators of cellular lipid metabolism is the sterol regulatory elementbinding protein (SREBP) family. These basic helix-loophelix-leucine zipper transcription factors stimulate the expression of genes involved in cholesterol, fatty acid, and triglyceride synthesis (Goldstein et al. 2006) . SREBPs are synthesized as precursor proteins in the endoplasmic reticulum (ER). Various stimuli such as the cellular concentration of sterol regulate the cleavage of the precursor membranebound form to release the mature nuclear form. The SREBP cleavage activating protein (SCAP), another ER membraneembedded protein, binds to SREBP and acts as a sterol sensor. When there is sufficient sterol in the cell, SCAP is bound to another ER membrane protein, insulin-induced gene (Insig), which prevents the SCAP-SREBP complex from moving to the Golgi apparatus. Upon sterol deprivation, the SCAP-SREBP complex dissociates from Insig and is transported to the Golgi where the sequential cleavage of the precursor protein by site-1 (S1P) and site-2 (S2P) proteases occurs. Once the N-terminal domain is released from SREBP, it translocates to the nucleus, binds to sterol response elements of cholesterol and fatty acid biosynthetic target genes and activates their transcription.
The SREBP family consists of three subtypes (two SREBP-1 splice variants SREBP-1a and SREBP-1c, and SREBP-2), which undergo similar proteolytic activation and overlap in function. Although SREBP-1 preferentially increases the transcription of genes involved in fatty acid and triglyceride synthesis, it also can activate genes for cholesterol synthesis. SREBP-2, however, primarily targets genes of the cholesterol biosynthetic pathway, including its rate-limiting enzyme hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR). The role of SREBPs in cellular lipid metabolism and homeostasis in liver and adipose tissue is well established, both under normal and pathological conditions (Horton et al. 2002; Moon et al. 2012) . Recently, studies have highlighted the importance of SREBP function in the peripheral nervous system (PNS) where Schwann cells express SREBPs in a developmentally regulated time frame (Verheijen et al. 2003; Leblanc et al. 2005; Camargo et al. 2009 ). Furthermore, a SCAP-mediated control of lipid metabolism is necessary for proper myelin synthesis in Schwann cells since deletion of the SCAP protein in mice resulted in congenital hypomyelination and an abnormal gait ). In the CNS, involvement of SREBPs is thought to include regulation of neurite outgrowth, synaptogenesis, and synaptic function ). The role of SREBPs in oligodendrocyte maturation, however, has not been explored despite the importance of lipids, especially cholesterol, for proper myelin formation (Saher et al. 2005) . Therefore, we investigated whether SREBPs play a role in the regulation of oligodendrocyte maturation. We found that blocking SREBP processing altered oligodendrocyte differentiation in vitro. Preventing SREBP maturation inhibited process growth from differentiating oligodendrocytes. This effect was accompanied by a reduction in the myelin protein MBP, whereas the immature oligodendrocyte marker GalC and PLP, another major myelin protein, were not affected. We also observed a dramatic down-regulation of genes for both fatty acid and cholesterol biosynthesis following inhibition of SREBP processing, which correlated with a decline in SREBP mRNA expression. Furthermore, protein levels of fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC), and HMGCR were dramatically reduced when SREBP maturation was prevented, and this effect correlated with decreased intracellular cholesterol synthesis. Finally, addition of cholesterol to the cultures at the onset of differentiation prevented the inhibition of process growth in maturing oligodendrocytes. Our data demonstrate that the control of lipid synthesis, notably cholesterol, via the SREBP pathway is essential for proper oligodendrocyte differentiation and myelin membrane production.
Materials and methods

Dissociated cerebral cortex oligodendrocyte cultures
All experiments were performed following the guidelines set forth by The Children's Hospital of Philadelphia Institutional Animal Care and Use Committee (IACUC). Cerebral cortices were isolated from newborn (males and females) CD1 mice (Charles River Laboratories, Malvern, PA, USA) with modifications from previously described protocols Jensen et al. 2015) Briefly, the tissue was minced, triturated in 0.3% trypsin (Life Technologies, Grand Island, NY, USA) at 37°C before 10% fetal bovine serum was added, and centrifuged at 200 g for 4 min. The supernatant was removed, Neurobasal medium (NBM; Life Technologies) supplemented with B27 containing 0.5 mM L-glutamine and 5000 U/mL Penicillin/Streptomycin was added, and the tissue dissociated by trituration. Cells were plated at 4 9 10 5 cells/mL on poly-D-lysine (PDL; 10 lg/mL; Sigma-Aldrich, St. Louis, MO, USA)-coated 100 mm cell culture dishes. After 24 h, the culture medium was replaced with growth medium (NBM/B27/L-glutamine/Penicillin/Streptomycin) containing 10 ng/mL basic fibroblast growth factor (bFGF; R&D Systems, Minneapolis, MN, USA) and 2 ng/mL platelet-derived growth factor alpha. Cells were grown at 37°C in 5% CO 2 and were fed growth medium every 2 days until they reached approximately 80% confluence. Enriched oligodendrocyte cultures were generated using a modified washdown procedure ). Cells were either plated at 0.8 9 10 5 cells/mL on PDL-coated glass coverslips in 24-well culture plates or at 1 9 10 5 cells/mL on PDL-coated 100 mm cell culture dishes. Cells were grown until they reached approximately 70% confluence, and then were switched to the differentiation medium (DM).
To differentiate OPCs into mature oligodendrocytes, the growth medium was replaced with DM, consisting of Dulbecco's modified Eagle's medium/F12 supplemented with N2 (Life Technologies), containing 2 mM L-glutamine, 30% D-glucose, 0.4 lg/mL L-Thyroxine (T4; Sigma-Aldrich), and 10 ng/mL biotin (SigmaAldrich).
Drug treatments
OPCs were placed into DM with or without S1P inhibitor PF-429242 (1-3 lM; Hay et al. 2007 ) for various periods of time. For reversibility experiments, cultures placed in DM were exposed to the S1P inhibitor for 3 days. Then, both S1P inhibitor-treated and control cultures were washed with fresh DM and incubated for an additional 1 day before analysis. For rescue experiments, OPC cultures were switched to DM-containing 1 lM water-soluble cholesterol (Sigma-Aldrich) in the presence or absence of 1 lM S1P inhibitor, and were allowed to differentiate for 3 days.
Cell viability
Cell survival was determined by incubating with 15 lg/mL fluorescein diacetate and 4.5 lg/mL propidium iodide (15 min, 37°C). Cells were counted in 12 microscopic fields at 209 magnification, in each of 4 wells per condition. Experiments were repeated at least 3 times. Cell survival was expressed as percent of control values and represents a minimum of 1000 cells counted per condition in each experiment.
Immunocytochemistry
Cells grown on coverslips were processed for detection of surface or internal antigens as previously described Jensen et al. 2015) . Table 1 shows primary antibody details and use. For cell surface antigen detection, live cells were labeled with anti-O4 or anti-GalC, then fixed in methanol. All coverslips were labeled with anti-Olig2. For detection of internal antigens, cells were fixed in methanol and incubated in anti-PLP hybridoma supernatant, anti-Olig2, anti-SREBP-1, or anti-SREBP-2. SREBP antibodies recognize both precursor and mature forms. Secondary antibodies of appropriate species and isotype used for external and internal antigens were purchased from Jackson Immunoresearch, West Grove, PA. Coverslips were mounted onto glass slides in DAPI (4 0 ,6-Diamidino-2-phenylindole dihydrochloride)-containing Vectashield mounting medium (Vector Laboratories, Burlingame, CA, USA). For phalloidin staining, cells were first immunolabeled with anti-O4 as described above, then fixed in 4% paraformaldehyde/4% sucrose, washed in phosphate-buffered saline, permeablized in 0.5% Triton X-100 followed by incubation with Phalloidin-Rhodamine (500 nM in BSA/CAS-Block; Sigma-Aldrich) for 2 h at 25°C.
Oligodendrocytes were visualized and fluorescent images recorded with a Leica DM6000B fluorescence microscope and analyzed with Leica LAS image analysis program.
Oligodendrocyte cell count
The oligodendrocyte lineage marker Olig2 (Zhou et al. 2000) was used to label both differentiating and undifferentiated (OPCs) oligodendrocytes. Double-immunolabeled oligodendrocytes for markers of differentiation and Olig2 were counted in 12 microscopic fields at 409 magnification, in each of 3-4 wells per condition. Experiments were repeated at least three times. Cell counts determined the number of O4, GalC, and PLP positive cells which exhibited a 'ring-like' morphology versus those which extended processes longer than two cell diameter using a reticle. Totals were expressed as percent of control values and represents a minimum of 1000 cells counted, per condition in each experiment.
Western blots
For whole cell extracts, cells were harvested in cold 25 mM Tris (pH 7.4), 1 mM EDTA, 1% sodium dodecyl sulfate, 1% Triton X-100, 150 mM NaCl containing protease and phosphatase inhibitor cocktails (PIs; Roche Diagnostics), sonicated and then centrifuged 20 min at 12 000 g. Cytosolic and nuclear extracts for detection of SREBP proteins were prepared by harvesting the cells in cold 10 mM Hepes, 10 mM NaCl, 10 mM EDTA, 1 mM dithiothreitol, 4% Triton X-100 containing PIs. Lysates were centrifuged 10 min at 12 000 g, the supernatant (cytosolic fraction) collected then stored at À80°C. To extract nuclear proteins, the pellet was resuspended in cold high salt buffer containing 20 mM Hepes, 400 mM NaCl, 1 mM EDTA, 10% glycerol, 1 mM dithiothreitol with PIs. Nuclear proteins were incubated on a rocking platform (200 rpm) for 2 h at +4°C. The debris was pelleted by centrifugation at 12 000 g and the supernatant, corresponding to the nuclear fraction, collected. Protein amounts were determined by bicinchoninic acid protein assay (Pierce, Rockford, IL, USA). Equal protein amounts were diluted in NuPAGE lithium dodecyl sulfate (LDS) buffer (Life Technologies) containing 2.5% b-mercaptoethanol and separated on NuPAGE Bis-Tris or Tris-Acetate gels and subsequently transferred to polyvinylidene difluoride (for MBP, PLP, GalC, Olig1, Olig2, and Sox10, containing 5% non-fat dry milk, the membranes were incubated with primary antibodies in TBST/5% bovine serum albumin (BSA) overnight at 4°C (Table 1) . When anti-PLP was used, NuPAGE gels were run under non-reducing conditions. Washed polyvinylidene difluoride membranes were incubated with IRDye 680RD goat antimouse IgG (1 : 12 000; Li-Cor, Lincoln, NE, USA), or IRDye 800CW goat anti-rat IgG (1 : 15 000) in TBST/5% BSA for 90 min at 25°C. Proteins were detected and quantified using the Odyssey infrared imaging system (Li-Cor). Washed nitrocellulose membranes were incubated with horseradish peroxidase (HRP)-linked donkey anti-rabbit IgG (1 : 1000; GE Healthcare, Piscataway, NJ, USA) or HRP-linked sheep anti-mouse IgG (1 : 1000; GE Healthcare) in TBST/5% BSA for 1 h at 25°C. Proteins were visualized, using Luminata Forte Western HRP substrate (Millipore Corporation, Bedford, MA, USA), and exposed to CL-Xposure films (Pierce). To quantify protein bands, the film was scanned and analyzed on a Macintosh computer using the public domain Java image processing and analysis program NIH ImageJ 1.47V inspired by the NIH Image developed at the US National Institute of Health and available on the internet at https://imagej.nih.gov/ij/. Band intensities were normalized, using a-tubulin or anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) signals, then calculated as a percentage of control bands in the same membrane. Experiments were repeated at least 3 times for data analysis.
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) Cells were harvested before (OPCs) and 1, 2 and 3 days into differentiation. Total RNA was extracted with Trizol (Molecular Research Center, Cincinnati, OH, USA) and then purified, using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). Two micrograms of purified RNA were converted into cDNA, using the Superscript III First-strand Kit (Life Technologies), and 80 ng of cDNA were used to perform qRT-PCR, using Power SYBR Green as previously described (French-Morein et al. 2009; Feigenson et al. 2011) . Primer sequences are listed in Table 1 . Samples were measured in triplicate for each experiment from three biological replicates. Data were normalized using Protein Kinase Gene 1 and were analyzed according to the comparative threshold (DDCT) cycle method. All experiments were repeated at least three times for data analysis.
Deuterium oxide (D 2 O) labeling and quantification of de novo cholesterol synthesis Cells in DM were switched to 5% D 2 O-containing labeling medium [DM + 5% D 2 O (Sigma-Aldrich)] for the last 7 h of the 3-day differentiation paradigm before they were harvested. 25-hydroxycholesterol was added as internal standard. Samples were saponified with KOH potassium hydroxide (0.3 M in ethanol) followed by incubation with BF 3 (15% in methanol). The reaction was stopped with water and the lipid fraction extracted into hexane, dried under nitrogen and then incubated at RT with pentafluorobenzoyl chloride (2.2% final concentration) in toluene-containing pyridine (8.8% final concentration) as a catalyst to form the pentafluorobenzyl ester of cholesterol. The reaction was stopped by addition of water and the 
fraction-containing derivatized cholesterol was extracted into petroleum ether. The derivatized cholesterol was analyzed by gas chromatography/ mass spectrometry (Agilent 7890A/5975), using negative chemical ionization (monitoring m/z 580-588 for cholesterol). Cholesterol was normalized to the internal standard and the concentration and isotopic enrichment determined, using an external standard curve. The percent of newly made cholesterol was determined using the equation:
where n is the number of exchangeable hydrogens incorporated into cholesterol, assumed to equal 26 (Previs et al. 2011 
Results
Expression of SREBPs in cultured cortical oligodendrocytes
The SREBPs are expressed in myelinating Schwann cells of the PNS in which they regulate myelin membrane formation (Verheijen et al. 2003; Leblanc et al. 2005; Camargo et al. 2009 ). To determine whether SREBPs were also expressed in oligodendrocytes, we used our well-established cell culture system in which enriched OPC cultures grown with growth factors are induced to differentiate into mature oligodendrocytes when growth factors are removed and cells are placed in DM. Thereafter, maturing oligodendrocytes sequentially express myelin markers over a 3-day period during which defined stages of differentiation can be followed. Cultured OPCs were switched to DM and grown for 3 days before cells were double-labeled with antibodies against PLP, a major protein of mature oligodendrocytes, and SREBP-1 or SREBP-2. Figure 1 (a and c) shows PLP-labeled oligodendrocytes displaying intense staining of processes and cell bodies. SREBP-1 was detected in all differentiated oligodendrocytes, and was mainly localized to the cell bodies, with additional punctate staining proximal to primary processes (Fig. 1b) . PLP-negative cells also expressed SREBP-1 in their cytoplasm with diffuse staining in their proximal processes, indicating that undifferentiated OPCs and contaminating astrocytes present in the cultures also express SREBP-1. SREBP-2 immunoreactivity was observed in differentiated oligodendrocytes, however, its localization was exclusively nuclear (Fig. 1d) . Similar to SREBP-1, PLP-negative cells also displayed SREBP-2 staining in their nuclei, indicating that SREBP-2 is also expressed in both OPCs and astrocytes. Thus, differentiated oligodendrocytes express both SREBPs, albeit at different cellular locations under our culture conditions. Next, we examined SREBPs' expression pattern in differentiating oligodendrocyte cultures by performing western blotting on cell extracts collected before (OPCs) and after 1, 2, and 3 days of differentiation. Both SREBP-1 (Fig. 1e ) and SREBP-2 (Fig. 1f) were expressed in OPC cultures and showed only slight variations in their expression levels during oligodendrocyte differentiation. However, assessing the transcriptional activity of their respective genes by qRT-PCR revealed an approximately 2.5-fold increase in SREBP-1 mRNA expression after 3 days of differentiation compared with its expression in OPCs, while that of SREBP-2 remained fairly unchanged ( Fig. 1g and h ).
Blocking SREBP processing through site-1 protease (S1P) inhibition alters oligodendrocyte differentiation Previous reports have established that the S1P inhibitor PF-429242 used in this study was highly selective for S1P and that it inhibited SREBP processing both in vitro and in vivo (Hay et al. 2007; Hawkins et al. 2008) . To confirm that S1P inhibition also blocked SREBP processing in our cell culture system, western blotting was used to assess the respective levels of the membrane-bound (precursor) and nuclear (mature) forms of SREBPs. Cells were switched to DM and incubated with or without S1P inhibitor (1 lM) for 1 or 3 days before being processed. In control cultures, both SREBP-1 forms were detected, whereas in PF-429242-treated cells, both forms were dramatically reduced after 24 h and 3 days of exposure (Fig. 2a) . The effect of S1P inhibitor on SREBP-2 precursor form was similar following 24 h and 3 days of treatment, however, S1P inhibition did not affect the expression of the mature form (Fig. 2b and c) . To determine whether the S1P inhibitor acted selectively on SREBPs' expression, we also analyzed its effect on Olig1, Olig2, and Sox10, major transcriptional regulators of oligodendrocyte differentiation (Emery and Lu 2015) . Western blot analyses performed on cell extracts from oligodendrocytes differentiated for 1 and 3 days revealed no changes in protein levels of these transcription factors following S1P inhibition, compared with controls ( Fig. 2f and g ). Both Olig1 and Olig2 were strongly expressed in OPCs and their expressions declined over time, whereas Sox10 0 s expression in OPCs was low and increased at 3 days. Thus, blocking S1P selectively prevents SREBP processing while other oligodendrocyte transcriptional regulators are not affected.
Since SREBPs can activate the transcription of their own genes, we examined whether preventing SREBP maturation through S1P inhibition would change SREBPs' mRNA expression levels. Results from qRT-PCR analysis performed on differentiating oligodendrocyte cultures for 1 to 3 days showed that SREBP-1 mRNA expression was dramatically reduced following exposure to S1P inhibitor (Fig. 2d) . In addition, SREBP-2 mRNA expression also was downregulated following S1P inhibition, albeit to a lesser extent (Fig. 2e) .
We next examined whether blocking SREBP processing would affect oligodendrocyte maturation by evaluating the effect of pharmacological inhibition of SREBP processing on the expression of O4, a late progenitor cell surface lipid antigen (Sommer and Schachner 1981) , GalC, an immature oligodendrocyte cell surface glycolipid marker (Ranscht et al. 1982) and PLP. In addition, cells were co-labeled with anti-Olig2 to account for all the oligodendrocyte lineage cells present in the culture. Cultured OPCs were switched to DM containing 1 lM PF-429242 and grown for 3 days, before immunostaining of stage-specific markers was performed. S1P inhibition greatly altered oligodendrocyte morphology, immunoreactivities from oligodendrocyte precursor cells (OPCs) and oligodendrocyte cultures after 1, 2 and 3 days in DM, normalized to GAPDH loading control. Graph data are expressed as mean AE SEM from 2 independent experiments. In (g and h), OPC and oligodendrocyte cultures grown for 1, 2 and 3 days in DM were subjected to qRT-PCR analysis to determine SREBP-1 (g) and SREBP-2 (h) mRNA expressions relative to that of OPCs. Graph data are expressed as mean AE SEM from 3 independent experiments. *p < 0.01, **p < 0.005, versus control.
as many cells had dramatically reduced process growth compared with controls (visualized with GalC staining), and displayed a 'ring-like' staining in which GalC expression was mainly concentrated around the cell body ( Fig. 3d ; quantified in 3H). The number of GalC-expressing, Olig2-positive cells that extended processes in PF-429242-treated cultures was reduced by 70% compared to controls (Fig. 3g) . Removing S1P inhibitor after 3 days followed by a 1-day washout completely reversed its effect: the number of GalCpositive 'ringed' cells was reduced to control levels, while GalC-positive cells displayed prominent process growth ( Fig. 4a and b) . Two other markers of early and late differentiation, O4 and PLP, respectively revealed a similar pattern of expression to that was observed with GalC ( Fig. 3b and f) . The number of both O4-and PLP-positive 'ringed' cells was > 50% of the total number of cells that stained positive for either marker in S1P inhibitor-exposed cells, whereas 'ring-like' staining was rarely observed in controls (Fig. 3a, e, i and j) . Regardless of this altered morphology, total numbers of GalC-positive, O4-positive, PLP-positive ('ringed' + normal process-bearing cells), and Olig2-positive cells were similar between controls and S1P inhibitor-treated cells. These data suggest that the sequential expression of these myelin markers was neither blocked nor delayed by inhibiting S1P. Cell viability was not affected by S1P inhibition (controls: 86.43 AE 6.53% viable cells; S1P-treated cells: 83.86 AE 7.46% viable cells; n = 2).
To determine whether the observed 'ring-like' morphology resulted from a lack of process extension and/or altered marker expression/distribution, we double-stained differentiating oligodendrocytes with anti-O4 and phalloidin-rhodamine to Fig. 2 Effect of site-1 protease (S1P) inhibition on SREBP proteins' expression (precursor and mature forms), mRNAs and oligodendrocyte transcription factors. (a, b and c) show western blots and densitometric analysis of SREBP-1 (a) and SREBP-2 (b) protein immunoreactivities from oligodendrocyte cultures grown with or without 1 lM S1P inhibitor after 1 and 3 days in differentiation medium (DM), with GAPDH as a loading control. Graph (c) represents the densitometric analysis of SREBP-2 mature form immunoreactivity normalized to its loading control shown in its respective western blot at 3 days. Graph data are expressed as mean AE SEM from 3 independent experiments. In (d and e), oligodendrocyte precursor cells (OPC) and oligodendrocyte cultures grown for 1, 2 and 3 days in DM with or without S1P inhibitor (1 lM) were subjected to qRT-PCR analysis to determine SREBP-1 (d) and SREBP-2 (e) mRNA expressions relative to that of OPCs. Graph data are expressed as mean AE SEM from three independent experiments. *p < 0.01, **p < 0.005, ***p < 0.0001 versus control. (f and g), show western blot and densitometric analyses of the effect of 1 lM S1P inhibitor on Olig1, Olig2, and Sox10 transcription factor immunoreactivities from cell extracts of differentiating oligodendrocytes after exposure for 1 and 3 days. Alpha-tubulin and GAPDH were used as loading controls. Representative blot data from 3 to 4 independent experiments. , anti-GalC (c and d) or anti-PLP (e and f) and grown in differentiation medium (DM) for 3 days without (a, c and e) or with 1 lM S1P inhibitor (b, d and f). In controls, oligodendrocyte differentiation marker immunoreactivity is present throughout the cell including its network of processes (a, c and e), whereas in S1P inhibitor's presence cell markers are primarily confined to the cell body (b, d and f). Corresponding DAPI staining of nuclei is shown for each panel. Scale bar: 25 lm. (g, h, i and j) show the quantification of the alteration of oligodendrocyte differentiation markers. In (g), the number of process-bearing GalC+ cells was quantified and normalized to the number of Olig2 + cells, and expressed as percent of control values. In (h, i and j), the number of 'ringed' cells for each marker of differentiation (O4, GalC or PLP) was normalized to the total number of cells (ringed + processbearing) expressing that particular marker. Data are expressed as mean AE SEM from 2 to 4 independent experiments. *p < 0.0001 vs. control. Site-1 protease (S1P) inhibition blocks process extension from differentiating oligodendrocytes and is reversible. (a) shows representative photomicrographs of oligodendrocytes labeled with anti-GalC and grown in differentiation medium (DM) for 3 days without or with 1 lM S1P inhibitor as indicated. Some cultures were exposed to S1P inhibitor for 3 days and then thoroughly washed and incubated in fresh DM for 1 more day without inhibitor. Controls were incubated in DM only. After 3 days in controls, GalC immunoreactivity is present throughout the cell including its processes, whereas with the S1P inhibitor most GalC expression is confined to the cell body (arrowheads). Removing the inhibitor allows for complete recovery of the altered GalC expression, which is present throughout the cell body and processes. Corresponding DAPI staining of nuclei (in blue) is shown for each panel. Scale bar:
25 lm. In (b), the graph represents the number of GalC+ 'ringed' cells normalized to the total number of GalC-expressing cells (ringed + process-bearing). Data are expressed as mean AE S.E.M. from 3 independent experiments. *p < 0.0001 versus control, **p < 0.0001 versus S1P inhibitor. (c) shows representative images of differentiating oligodendrocytes grown for 3 days without (a and b) or with 1 lM S1P inhibitor (c and d). Cells were triple-labeled with anti-O4 to label oligodendrocytes (green), phalloidin to label F-actin (red) and DAPI to stain nuclei (blue). In both Control and S1P-exposed cells, O4 and phalloidin staining mostly overlap (yellow circles in b and d refer to corresponding O4 + cells in a and c). In S1P-treated cells, phalloidin staining reveals that differentiating oligodendrocytes' process growth does not extend beyond that of O4 staining. Scale bar: 25 lm.
visualize F-actin-containing processes. Figure 4b shows control cells displaying highly branched O4-positive processes which co-labeled with phalloidin. As expected, S1P inhibitortreated cells displayed stunted process growth, however, phalloidin staining reveal no further process extension beyond that overlapped with O4 labeling (Fig. 4d) . Thus, S1P inhibition prevents process growth from differentiating oligodendrocytes. We asked if process growth inhibition was accompanied by altered expression levels of myelin proteins. Western blot analysis for the immature oligodendrocyte marker GalC and two major myelin proteins, PLP and MBP, was carried out after 3 days in DM, both in control and PF-429242-treated cells. Densitometric analysis of protein bands on western blots showed similar levels of GalC and PLP expressions in control and PF-429242-exposed cultures after 3 days ( Fig. 5a and b) . However, MBP levels were significantly reduced following S1P inhibitor treatment (Fig. 5c) . We examined whether decreased MBP expression correlated with a reduction in MBP mRNA levels as well, by performing qRT-PCR on differentiating oligodendrocyte cultures with or without S1P inhibitor for 1-3 days. Both control and S1P-treated cells exhibited a dramatic increase in MBP transcriptional activity as maturation proceeded -c) show western blot and quantification of band intensities of S1P inhibitor's effect on PLP (a), galactocerebroside (GalC) (b) and myelin basic protein (MBP) (c) immunoreactivities from differentiating oligodendrocytes exposed to 1 lM S1P inhibitor for 3 days with a-tubulin (a and c) or GAPDH (b) as loading controls. Graph data are expressed as mean AE SEM from 3 to 4 independent experiments. *p < 0.005 versus control. (d) oligodendrocyte precursor cell (OPC) and oligodendrocyte cultures grown for 1, 2 and 3 days in differentiation medium (DM) were subjected to qRT-PCR analysis to determine MBP mRNA expression relative to that of OPCs and S1P inhibition's effect (1 lM PF-429242). Graph data are expressed as mean AE SEM from 3 independent experiments. (e) western blot analysis of S1P inhibitor's effect on phospho-Tyr530-Fyn and Fyn immunoreactivities from cell extracts from differentiating oligodendrocytes exposed to 1 lM S1P inhibitor for 1, 2 and 3 days. GAPDH was used as loading control. Representative blot data from 2 to 4 independent experiments.
( Fig. 5d) , suggesting that impaired MBP expression levels likely occurred post-transcriptionally.
The morphological differentiation of oligodendrocytes is accompanied by rearrangement of the actin cytoskeleton, in part through the control of Fyn kinase, a member of the Src family of cytoplasmic non-receptor tyrosine kinases (Kramer-Albers and White 2011). Fyn inactivation, however, interferes with process growth of oligodendrocytes (Osterhout et al. 1999) . Therefore, we investigated whether S1P inhibition blocked Fyn activation as a mechanism by which process extension from oligodendrocytes was impaired. Cells were switched to DM and incubated with or without S1P inhibitor for 1-3 days before being processed for western blot analysis with anti-phospho-Tyr530-Fyn. Dephosphorylation of Tyr 530 is one of the two crucial steps involved in Fyn activation (Cole et al. 2003) . However, S1P inhibition altered neither phospho-Tyr530-Fyn nor total Fyn expression levels during oligodendrocyte differentiation (Fig. 5e ).
S1P inhibition down-regulates the transcription of SREBP target genes
The SREBPs stimulate the transcription of numerous genes involved in lipid synthesis, among which FASN, ACC and HMGCR are main targets. Therefore, we investigated their expression, during normal oligodendrocyte differentiation and following S1P inhibition. Consistent with SREBP-1 upregulation under normal conditions and its primary activity as transcription factor for fatty acid and triglyceride synthesis, mRNA expression levels for FASN and ACC increased rapidly following the onset of differentiation compared with their expression in OPCs (Fig. 6a and b) . Although SREBP-2 mRNA expression remained unchanged during normal differentiation, HMGCR gene expression, one of the cholesterol synthetic pathway genes preferentially regulated by SREBP-2, was also increased when cells were undergoing differentiation under normal conditions (Fig. 6c) .
Since the transcriptional activity of SREBPs themselves was reduced in the presence of PF-429242, we examined whether the regulation of SREBP target genes also was impaired by S1P inhibition. As shown in Fig. 6(a and c) , the expression of both the endogenous SREBP-1 target gene FASN and the SREBP-2 target gene HMGCR was significantly decreased following S1P inhibition at 1, 2 and 3 days after inhibitor treatment, compared with controls. The mRNA expression for ACC was also reduced in the presence of S1P inhibitor, and this effect was significant after 2 and 3 days of treatment (Fig. 6b) . S1P inhibition decreases the expression and activity of key enzymes in both the fatty acid and the cholesterol pathways Our data showed that the S1P inhibitor-induced blockade of SREBP maturation reduced the expression of genes from both the fatty acid (FASN and ACC) and the cholesterol (HMGCR) pathways. To determine whether this effect led to altered FASN, ACC or HMGCR protein levels, oligodendrocytes were differentiated for 3 days before cell extracts were analyzed by western blotting. As shown in Figure 6d a sharp decrease in the expression of both fatty acid pathway Fig. 6 Effect of S1P inhibition on SREBP target gene mRNA and protein expressions. In (a, b and c), oligodendrocyte cultures grown for 1, 2, and 3 days in a differentiation medium (DM) with or without 1 lM PF-429242 were subjected to qRT-PCR analysis to determine fatty acid synthase (FASN), acetyl CoA carboxylase (ACC), and hydroxy-methyl-glutaryl CoA reductase (HMGCR) mRNA expressions relative to that of oligodendrocyte precursor cells (OPCs). Graph data are expressed as mean AE SEM from 3 independent experiments. *p < 0.05, **p < 0.01, versus control. (d) shows western blot of FASN, ACC, and HMGCR protein immunoreactivities from oligodendrocyte cultures grown with or without 1 lM PF-429242 after 3 days in DM. GAPDH was used as loading control. Graph data are representative of three independent experiments.
proteins was observed, demonstrated by a 70% reduction (controls: 19.8 AE 1.3; S1P-treated cells: 5.2 AE 1.02; n = 4) and 50% reduction (controls: 17.05 AE 1.12; S1P-treated cells: 7.93 AE 1.2; n = 4) in band intensities of FASN and ACC protein levels, respectively. Band intensities representing HMGCR protein levels were reduced by approximately 20% following S1P inhibition (controls: 111.28 AE 17.5; S1P-treated cells: 87.78 AE 11.1; n = 4), although this was not statistically significant.
Our results indicated that mRNA and protein levels of key enzymes in the fatty acid and the cholesterol pathways were reduced when SREBP processing was prevented. Therefore, we asked whether lipid synthesis also was altered following S1P inhibition. Cholesterol is required for myelin synthesis and its availability is a rate-limiting factor, therefore, we determined de novo synthesis of cholesterol by employing deuterium oxide (D 2 O) labeling of lipids and mass spectrometry. de novo levels of cholesterol were drastically altered in S1P inhibitor-treated cells, demonstrated by a 70% reduction in cholesterol synthesis compared with controls [controls (ng/mg protein): 2336.4 AE 389; S1P-treated cells: 701.9 AE 112; n = 3]. Total cholesterol content also decreased more than 40% after S1P inhibitor treatment compared with controls (controls (lg/mg protein): 129.8 AE 13.5; S1P-treated cells: 73.6 AE 4.6; n = 3).
Addition of extracellular cholesterol prevents the S1P inhibitor-induced morphological alteration in oligodendrocyte differentiation Cholesterol is an important component of myelin membranes and in particular lipid rafts, which associated signaling is crucial in maintaining oligodendrocyte process integrity. Therefore, we determined whether adding cholesterol to the culture medium could counteract the S1P inhibitor-induced alteration in oligodendrocyte differentiation. Cultured OPCs were switched to DM containing cholesterol in the presence or absence of S1P inhibitor for 3 days. Co-treatment of Fig. 7 Extracellular cholesterol addition prevents S1P inhibitorinduced morphological alteration from differentiating oligodendrocytes. (a) shows representative photomicrographs of oligodendrocytes labeled with anti-O4 and grown either in cholesterol-supplemented (1 lM) or in regular differentiation medium (DM) for 3 days without or with 1 lM S1P inhibitor, as indicated. Controls were incubated in DM without or with cholesterol only. In controls, O4 immunoreactivity is present throughout the cell including its processes, whereas with the S1P inhibitor alone, 'ringed' O4 + cells are prominently seen. Addition of extracellular cholesterol rescued the S1P inhibitor-induced altered O4 expression, which is present throughout the cell body and processes. DAPI staining of nuclei (in blue) is shown. Scale bar: 25 lm. In (b), the graph represents the number of O4 + 'ringed' cells normalized to the total number of O4-expressing cells (ringed + process-bearing). Data are expressed as mean AE SEM from 3 independent experiments. *p < 0.0001 versus control, cholesterol and S1P inhibitor + cholesterol.
cultures with 1 lM PF-429242 and 1 lM cholesterol prevented the formation of 'ringed' O4-positive cells observed in S1P inhibitor-treated cells (Fig. 7a and b) . In addition, cells treated with both compounds displayed prominent process extension similar to controls or cells incubated with cholesterol alone (Fig. 7a) . These data suggest that addition of extracellular cholesterol can rescue the morphological alteration of oligodendrocytes, compensating at least in part for the decrease in de novo intracellular cholesterol synthesis that is observed when SREBP processing is prevented.
Discussion
SREBPs are important regulators of cholesterol and lipid metabolism but their role in oligodendrocyte maturation is unknown. The present study demonstrates that SREBP processing is necessary for proper oligodendrocyte differentiation and in particular process extension. In addition, S1P inhibition altered the expression of MBP, one of the major myelin proteins. Furthermore, transcription of target genes of SREBPs, including SREBPs themselves and their associated proteins, also was dysregulated if proteolytic cleavage of SREBPs was inhibited. Thus, both morphological and biochemical alterations may occur in differentiating oligodendrocytes when SREBP maturation is prevented.
The potent and specific cell-permeable small molecule inhibitor PF-429242 used in this study was previously shown to efficiently block S1P-mediated processing of SREBPs in vitro and in vivo at doses that ranged from 1 to 10 lM (Hay et al. 2007; Hawkins et al. 2008; Blanchet et al. 2012; Bitter et al. 2015) . Consistent with this, 1 lM of PF-429242 effectively blocked SREBP processing in our cell culture system.
The effect of S1P inhibition was most prominent on SREBP-1 processing, since both precursor and mature forms were decreased, whereas only the SREBP-2 precursor form was reduced following PF-429242 treatment. Decreased SREBP precursor protein expression after S1P inhibition has been reported in vitro (Bitter et al. 2015; Hawkins et al. 2008) and in S1P knockout mice (Yang et al. 2001) . In these animals, a decline in both SREBP precursor and mature forms was observed which correlated with a reduction in SREBP mRNA levels. Since SREBPs activate the transcription of their own genes, the decrease in both precursor forms reported by Yang et al. (2001) was interpreted as a consequence of SREBP mRNA down-regulation. Likewise, in our experiments, both SREBP precursor forms were decreased, consistent with the reduction in SREBP mRNA levels we observed following S1P inhibition. It is unclear why the SREBP-2 mature form was not reduced by PF-429242 treatment. However, it is possible that preferential cleavage of SREBP-1 by S1P occurred in our cell culture conditions, or that blocking the proteolytic activity of S1P or S2P may produce differing effects. SREBP regulation has proven to be very complex, thus differential regulation, stability of the proteins and/or processing of SREBPs may account for the unchanged level of SREBP-2 mature form we observed. Nevertheless, we found that both SREBP mRNAs were significantly decreased following S1P inhibition. Recently, Duvel et al. (2010) observed that SREBP-1-specific siRNAs also down-regulated SREBP-2 transcript levels. Therefore it is possible that reduced mature SREBP-1 level also affected the transcription of SREBP-2 mRNA in our system.
In agreement with the role of SREBP-1 in fatty acid synthesis, PF-429242 treatment resulted in down-regulation of the expression of the lipogenic target genes FASN and ACC. This reduction in turn correlated with dramatically reduced levels of both proteins. Decreased expression of genes and their respective proteins required for fatty acid synthesis following SREBP-1 inhibition was also reported in other studies including in Schwann cells (Bitter et al. 2015; Hawkins et al. 2008; Norrmen et al. 2014) . Although S1P inhibition did not reduce the levels of SREBP-2 mature form, diminished HMGCR mRNA expression was observed which was associated with a more modest reduction at the protein level than what was detected for FASN and ACC. Norrmen et al. (2014) also reported strong down-regulation of HMGCR mRNA expression without a reduction in SREBP-2 protein levels in Schwann cells. Regulation of SREBP-2 activity at the post-translational level may help explain the decreased expression of SREBP-2 target gene we observed in our experiments. Still others found reduced levels of expression of SREBP target genes and their respective proteins, including FASN, despite no change in SREBP-1 protein levels . Alternatively, the decrease in SREBP-1 we observed following S1P inhibition, may lead to a reduction in HMGCR mRNA expression since the SREBP-1a isoform also can activate genes involved in cholesterol synthesis (Shimano et al. 1997) .
The blockade of S1P proteolytic activity by PF-429242 had a dramatic effect on oligodendrocyte morphology. Regardless of the stage-specific markers used, we observed a significant reduction in process growth from PF-429242-exposed oligodendrocytes compared with controls. This effect was accompanied by a redistribution of the early and intermediate cellular markers of differentiation O4 and GalC, respectively, and the myelin protein PLP around the cell body, without affecting the expression levels of either GalC or PLP. One exception is MBP, whose protein level was decreased in the presence of PF-429242. However, unlike most myelin proteins that are translated in the perinuclear endoplasmic reticulum, trafficked through the secretory pathway and inserted into the forming myelin membrane, MBP mRNA is trafficked to sites proximal to membrane insertion where the protein is translated on free-ribosomes (Colman et al. 1982; Ainger et al. 1997) . Therefore, it is likely that the drastic reduction in process growth from PF-429242-treated oligodendrocytes prevented proper transport and translation of MBP mRNA. In support of this, we show that MBP mRNA expression was not affected by S1P inhibition. In contrast, blocking S1P activity does not prevent the expression of markers of oligodendocyte differentiation, like PLP, that are synthesized through the secretory pathway.
We also examined Fyn kinase activation since it is a key event for the morphological differentiation of oligodendrocytes that involves reorganization of actin microfilaments, and these play a major role in process extension (KramerAlbers and White 2011). Fyn inactivation interferes with oligodendrocyte process growth (Osterhout et al. 1999) . However, we did not observe a change in the phosphorylation level of tyrosine 530 which is essential for Fyn activation, indicating that a S1P inhibition-induced reduction in Fyn activation is unlikely.
By contrast, the mechanism by which a decline in SREBP processing through S1P inhibition leads to stunted process growth from oligodendrocytes may involve a reduction in intracellular cholesterol synthesis. Indeed, the process inhibition we observed was rescued by application of extracellular cholesterol, a method which was also successfully used to increase membrane cholesterol levels in hippocampal neurons and astrocytes (Abramov et al. 2011) . Cholesterol is an important component of myelin membranes and in particular lipid rafts, which signaling is crucial in maintaining oligodendrocyte process integrity. When disrupted, oligodendrocyte process outgrowth is impaired (Decker and Ffrench-Constant 2004; Liang et al. 2004) . In particular, reduced process outgrowth was reported in oligodendrocyte cultures following statininduced inhibition of HMGCR, the rate-limiting enzyme in the cholesterol biosynthesis pathway (Miron et al. 2007; Smolders et al. 2010) . Miron et al. (2007) also showed that process retraction from OPCs was rescued by cholesterol treatment. Our results are consistent with these studies in which inhibition of HMGCR-mediated cholesterol synthesis led to altered process growth from oligodendrocytes.
In addition to their important role in lipid metabolism, SREBPs are involved in other cellular processes such as autophagy, membrane biogenesis, and excitotoxicity (Shao and Espenshade 2012) . A genome-wide ChiP-Seq analysis of SREBP-1 binding in mouse liver not only identified clusters of target genes in lipid and carbohydrate metabolism, but also genes associated with cell proliferation and differentiation, protein phosphorylation, cell adhesion and cell structure, and motility (Seo et al. 2009 ). Thus, more functions of SREBPs are being found that are not directly related to lipid metabolism, which could also play a role in the morphological alteration we observed during oligodendrocyte differentiation. However, our observation that treatment of oligodendrocytes with PF-429242 did not alter the expression of three key transcription factors necessary for oligodendrocyte differentiation but exogenous cholesterol rescued the differentiation defect suggest that lipid biosynthesis is a critical action of SREBP in oligodendrocyte differentiation.
In conclusion, we show that SREBPs play a major role in oligodendrocyte maturation. Inhibition of SREBP activation stopped process extension, diminished myelin protein expression and decreased cholesterol synthesis. All these effects may contribute to impaired myelin formation, especially alterations in lipid synthesis, as myelin is highly enriched in lipids and therefore most vulnerable to perturbations in lipid metabolism. In particular, cholesterol is essential for the development of myelin and only very limited changes in the CNS myelin lipid composition can be accommodated. Therefore, reduced cholesterol synthesis may prevent proper myelin biogenesis and impair its function. In addition, a link between inhibition of lipid synthesis in transgenic mice over-expressing lamin B1 in oligodendrocytes and demyelination has recently been established by Rolyan et al. (2015) , highlighting the importance of the regulation of lipid synthesis not only during the formation of myelin but also for its maintenance. Elucidating the role of SREBPs in myelination may not only help our understanding of the mechanisms regulating basic myelin biology, but may also provide a foundation for future therapeutic interventions in various lipid metabolism disorders in which myelin integrity is impaired.
